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Patients: Cohort of 23,984 patients treated with recombinant human GH (r-hGH) in eight European
countries since this treatment was first used in 1984. Cancer expectations from country-specific
national population statistics.
Main Outcome Measures: Cancer incidence and cancer mortality.
Results: Incidence and mortality risks in the cohort were raised for several cancer sites, largely
consequent on second primary malignancies in patients given r-hGH after cancer treatment. There
was no clear raised risk in patientswith growth failurewithout othermajor disease. Only for bone and
bladder cancers was incidence significantly raised in GH-treated patients without previous cancer.
Cancer riskwas unrelated to duration or cumulative dose of r-hGH treatment, but for patients treated
after previous cancer, cancer mortality risk increased significantly with increasing daily r-hGH dose
(P trend , 0.001). Hodgkin lymphoma (HL) incidence increased significantly with longer follow-up
(P trend = 0.001 for patients overall and 0.002 for patients without previous cancer).
Conclusions: Our results do not generally support a carcinogenic effect of r-hGH, but the
unexplained trend in cancer mortality risk in relation to GH dose in patients with previous
cancer, and the indication of possible effects on bone cancer, bladder cancer, and HL risks, need
further investigation. (J Clin Endocrinol Metab 102: 1661–1672, 2017)
Growth hormone (GH) has been prescribed since1957 to treat GH deficiency and short stature due to
other causes. The hormone used was initially extracted
from human pituitaries (p-hGH), but after an outbreak of
Creutzfeldt–Jakob disease consequent on prion infection
from these pituitaries, this was discontinued in 1985 and
all subsequent treatment has been with recombinant
human growth hormone (r-hGH).
GH raises serum concentrations of insulin-like growth
factor (IGF)-1, which is mitogenic and antiapoptotic
in vitro, and adult levels of which have been associated in
most studies with risks of subsequent breast, colorectal,
and prostate cancers and in some studies with other
cancers (1, 2). Furthermore, cohort studies of patients
with endogenously raised GH concentrations, acro-
megaly, have found raised risks of several cancers, most
consistently colorectal (3, 4). Potential effects on leuke-
mia (5, 6) and other malignancy (1) risks have been
suggested, and second primary malignancy risk has been
shown raised in patients receiving GH after childhood
cancer (7, 8). Although these data give suspicion that
there might be carcinogenic effects, no risks have been
shown consistently or established. Cohort studies of
r-hGH treatment have either comprised at most a few
hundred patients (7, 9) or been conducted by pharma-
ceutical companies (10–14) with too short follow-up to
cover the likely lag period of carcinogenesis, and there has
been an absence of dose- and duration-response data. We
therefore assembled a large cross-European cohort,
the Safety and Appropriateness of Growth Hormone
Treatments in Europe (SAGhE) study, with follow-up
and analysis independent of pharmaceutical companies,
to examine whether treatment with r-hGH affects cancer
incidence and mortality risks in patients who have taken
this treatment.
Materials and Methods
In each of eight European countries (Table 1), we assembled
cohorts of patients treated with r-hGH at pediatric ages since
such treatment was first used in that country (1984 to 1986,
depending on the country) and never treated with p-hGH. Data
on demographic and GH-related variables were extracted from
existing databases and case notes. Subjects were followed for
mortality and cancer incidence via national population-based
registries in Belgium, the Netherlands, Sweden, and the United
Kingdom and by a range of methods in the other four countries.
Details are given in (15).
In each country, appropriate ethics committee agreement
was obtained. For all patients, either we obtained written in-
formed consent or an ethics committee decided that consent was
not required.
In Belgium, France, the Netherlands, Sweden, and the United
Kingdom, the cohorts were national and population-based, or
virtually so, whereas in Switzerland, Germany, and Italy, they
were mainly clinic-based and subnational. Vital status follow-
up was highly complete except for uncertainty on this in France
and Italy (15). Cancer incidence follow-up based on cancer
registration was highly complete in Belgium, the Netherlands,
Sweden, Switzerland, and the United Kingdom, but less complete
in France, Germany, and Italy, where there was no national cancer
registration. We therefore restricted cancer incidence risk calcu-
lations to the former five countries (15) and present numbers of
cancers from the latter three in the Supplemental Data.
Because certain rare conditions (e.g., neurofibromatosis) that
lead to GH therapy are themselves strong predisposing factors
for cancer, we followed previous practice (11, 12, 16) in ex-
cluding individuals with such conditions (listed in Supplemental
Data) from analysis.
Statistical analysis
We calculated person-years at risk for cancer incidence
and mortality and used these with national population rates
to calculate standardized mortality ratios, standardized in-
cidence ratios (SIRs), absolute excess rates, and trends in risk
(17) by standard methods, as detailed in the Supplemen-
tal Data. The analyses investigated risks of all primary
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malignancies except nonmelanoma skin cancer, for which
cancer registration tends to be highly incomplete. All P values
are two sided.
Results
After exclusions for high-risk diagnoses, data unavail-
ability and lack of permission (see Supplemental Data
and Fig. 1), the cohort for mortality risk analyses
comprised 23,984 patients and for cancer incidence
10,406 patients. (For a further 9908 from France,
Germany, and Italy, incident cancers are reported in
the Supplemental Data, but risks are not analyzed; see
Methods). Half the cohort was first treated at ages 10
to 14, and about half received GH for isolated growth
failure (Table 1).
Follow-up for mortality totaled 396,344 person-years,
an average of 16.5 years per patient, and for cancer in-
cidence, 154,371 person-years, averaging 14.8 years per
patient. The mean age at the end of follow-up was 27.1
years for the cancer mortality analyses and 25.8 years for
the incidence analyses. There were 251 cancer deaths in
the cohort and 137 incident cancers in the countries for
which incidence risk was analyzed.
Cancer risks in the cohort overall
Cancer mortality in the cohort overall was over 13-
fold raised, and cancer incidence risk doubled (Table 2).
Absolute excess rates were 5.9 [95% confidence interval
(CI), 5.1 to 6.7] for cancer mortality and 4.8 (95%CI, 3.4
to 6.4) for cancer incidence. There was significantly
Table 1. The SAGhE Cohort: Descriptive Variables
Characteristic
Mortality Cohorta Cancer Incidence Cohorta
n % n %
Sex
Male 13,268 55.3 11,002 54.2
Female 10,716 44.7 9312 45.8
Country
Belgium 1363 5.7 1327 6.5
France 10,202 42.5 8614 42.4
Germany 1779 7.4 558 2.7
Italy 1361 5.7 736 3.6
The Netherlands 1746 7.3 1685 8.3
Sweden 2955 12.3 2822 13.9
Switzerland 743 3.1 737 3.6
United Kingdom 3835 16.0 3835 18.9
Age started GH treatment (y)
0–4 2008 8.4 1801 8.9
5–9 7665 32.0 6535 32.2
10–14 12,136 50.6 10,181 50.1
15–19 2175 9.1 1797 8.8
Year started GH treatment
,1990 5239 21.8 4685 23.1
1990–1994 10,394 43.3 9264 45.6
1995–1999 5796 24.2 4598 22.6
$2000 2555 10.7 1766 8.7
Diagnosis leading to GH treatment
CNS tumor 2221 9.3 1357 6.7
Non-CNS solid tumor 151 0.6 100 0.5
Hematological malignancy 730 3.0 428 2.1
Chronic renal failure and renal diseases 288 1.2 155 0.8
Turner syndrome 3503 14.6 3189 15.7
Other syndromes and chronic diseases 1446 6.0 1264 6.2
Multiple pituitary hormone deficiency 2497 10.4 2261 11.1
Skeletal dysplasias 358 1.5 337 1.7
Isolated growth failureb 12,468 52.0 11,062 54.5
Nonclassifiable 322 1.3 161 0.8
Total 23,984 100.0 20,314c 100.0
Abbreviation: CNS, central nervous system.
aSubjects included in follow-up for mortality, and for cancer incidence, excluding “high risk” initial diagnoses (see Methods).
bIncluding isolated GH deficiency, idiopathic short stature, and prenatal growth failure (small for gestational age).
cA total of 10,406 of these subjects were from Belgium, the Netherlands, Sweden, Switzerland, and the United Kingdomand are included in the person to
years–based analyses of cancer incidence risk presented in Tables 2 through 5 and Supplemental Tables 1 and 2; 9908 are from France, Germany, and Italy
and are presented in the Supplemental data for the reasons specified in the Methods.
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raised risk of both cancer mortality and incidence for
cancers of the bone, kidney, central nervous system
(CNS), and thyroid and significantly raised risks based
on .1 case for mortality from tongue, mouth, and
pharynx cancer; soft tissue cancer; non-Hodgkin lym-
phoma (non-HL) and leukemia; and incidence of mela-
noma and ovarian and bladder cancers. With the
exception of bone and bladder cancers, these raised risks
were essentially a consequence of risks in patients whose
original diagnosis leading toGH treatment was cancer. In
patients treated after cancer, there was additionally a
significantly raised risk based on .1 case for colorectal
cancer incidence. Risk estimates for the major adult
cancers (e.g., breast, lung, and prostate) had wide CIs,
based on few person-years of follow-up.
Risks by underlying diagnosis
In patients whose initial diagnosis was “isolated
growth failure” (i.e., growth failure without other major
disease: isolated GH deficiency, idiopathic short stature,
and prenatal growth failure), overall cancer risk was not
raised and there were no significantly raised site-specific
risks, based on small numbers of cases (Table 3). For
patients whose initial diagnosis was not isolated growth
failure or cancer, there were significantly raised risks of
cancer incidence (SIR = 1.4; 95% CI, 1.1 to 1.9) and
mortality (standardized mortality ratio = 2.2; 95% CI,
1.3 to 3.7) overall, and of bone (SIR = 4.1; 95%CI, 1.3 to
12.6) and bladder (SIR = 27.8; 95% CI, 7.0 to 111.3)
cancer incidence, reflecting cases after several different
initial diagnoses, with no obvious common factor, al-
though based on small numbers for each cancer site.
Risks by demographic characteristics and GH
treatment variables
Cancer risks in the cohort were similar in males and
females (Table 4). Risks varied over twofold between
countries, paralleling approximately the proportions of
subjects in these countries who had cancer as their initial
diagnosis (15). Cancer risk did not relate to age at starting
r-hGH treatment. For cancer mortality but not incidence,
risk decreased with longer duration since starting treat-
ment, and for cancer mortality especially, risk decreased
with longer duration of treatment. The effect of duration
of treatment disappeared for cancer incidence (P = 0.72)
and greatly diminished for cancer mortality (P = 0.04)
when we censored from analysis the person-time during
treatment plus the first 2 years after ending treatment (not
in Tables 1 through 5), suggesting that it had been an
artifact of cessations of treatment because of cancer oc-
currence. Risk of cancer incidence but not mortality
decreased with increasing mean GH dose, and both in-
cidence and mortality risks tended to diminish with
cumulative dose.
Figure 1. Numbers of patients recruited, excluded, and analyzed, SAGhE cohort.
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Examining these risks within the patients whose initial
diagnosis was cancer (Table 4), the only indications of
different patterns from those listed previously were that
incidence as well as mortality decreased with duration
since starting treatment and duration of treatment, cu-
mulative GH dose did not significantly affect mortality or
incidence, and mortality but not incidence increased
highly significantly (P, 0.001) with increasingmeanGH
dose. For patients whose initial diagnosis was not cancer,
neither cancer mortality nor incidence was significantly
related to any of the treatment variables. The diminutions
in risk seen with mean GH dose and cumulative dose for
cohort members overall were at least in part due to
confounding by initial diagnosis: Patients with initial
noncancer diagnoses tended to have received greater
mean and cumulative GH doses than did cancer patients
(e.g., 33% of noncancer patients but only 17% of cancer
patients received doses of $30 mg/kg/d). Analyses sep-
arately for patients with isolated growth failure, and for
those with Turner syndrome (Supplemental Table 1),
showed significant rising incidence risks with time since
first treatment and with duration of treatment (both
P = 0.02) for isolated growth failure patients, but oth-
erwise no significant risks for incidence or mortality.
Table 2. Cancer Mortality and Incidence Risks, SAGhE Cohort, by Site and Initial Diagnosis Leading to
GH Treatment
Outcome
All Initial Diagnoses Initial Diagnosis Cancer Initial Diagnosis Noncancer
Cancer Mortality Cancer Incidencec Cancer Mortality Cancer Incidencec Cancer Mortality Cancer Incidencec
ICD 10, C
code Cancer sitea n
SMRb
(95% CI) n
SIR
(95% CI) n
SMRb
(95% CI) n
SIR
(95% CI) n
SMRb
(95% CI) n
SIR
(95% CI)
01–14 Tongue, mouth,
pharynx
3 6.8
(2.2–21.2)*
1 1.4
(0.0–7.5)
2 24.2
(6.1–96.8)**
1 7.9
(0.2–43.8)
1 2.8
(0.1–15.7)
0 0.0
(0.0–6.0)
18–21 Colon and
rectum
2 3.6
(0.9–14.6)
4 2.3
(0.9–6.2)
1 14.7
(0.4–81.7)
2 7.4
(1.9–29.7)*
1 2.1
(0.1–11.6)
2 1.4
(0.3–5.6)
25 Pancreas 1 7.7
(0.2–42.6)
0 0.0
(0.0–28.0)
1 61.6
(1.6–343.4)*
0 0.0
(0.0–182.7)
0 0.0
(0.0–32.2)
0 0.0
(0.0–33.1)
33–34 Lung 1 1.9
(0.1–10.9)
1 2.6
(0.1–14.5)
0 0.0
(0.0–62.2)
0 0.0
(0.0–57.0)
1 2.2
(0.1–12.3)
1 3.1
(0.4–22.2)
40–41 Bone 12 6.9
(3.9–12.1)***
9 5.2
(2.7–10.1)***
8 35.5
(17.7–70.9)***
5 17.2
(7.2–41.4)***
4 2.6
(1.0–7.0)
4 2.8
(1.1–7.5)*
43 Melanoma 1 1.4
(0.0–8.0)
12 2.1
(1.2–3.8)*
0 0.0
(0.0–41.4)
5 5.8
(2.4–13.9)**
1 1.7
(0.0–9.2)
7 1.5
(0.7–3.1)
47–49 Soft tissue 5 5.9
(2.5–14.2)**
4 2.7
(1.0–7.2)
5 47.2
(19.7–113.4)***
2 8.5
(2.1–33.9)*
0 0.0
(0.0–5.0)
2 1.6
(0.4–6.4)
50 Breast 1 1.9
(0.1–10.4)
2 0.9
(0.2–3.4)
1 16.9
(0.4–94.1)
1 3.0
(0.1–16.6)
0 0.0
(0.0–7.7)
1 0.5
(0.0–2.8)
51 Vulva 0 0.0
(0.0–1749.0)
1 5.0
(0.1–27.8)
0 0.0
(0.0–9281.9)
0 0.0
(0.0–141.6)
0 0.0
(0.0–2155.1)
1 5.7
(0.2–31.9)
53 Cervix 0 0.0
(0.0–18.8)
17 0.9
(0.6–1.5)
0 0.0
(0.0–128.6)
2 0.8
(0.2–3.2)
0 0.0
(0.0–22.0)
15 0.9
(0.6–1.5)
54–55 Corpus uteri 1 24.3
(0.6–135.4)
0 0.0
(0.0–35.4)
1 259.7
(6.6–1446.7)**
0 0.0
(0.0–240.9)
0 0.0
(0.0–98.9)
0 0.0
(0.0–41.4)
56 Ovary 1 4.2
(0.1–23.4)
4 3.0
(1.1–7.9)*
1 39.7
(1.0–221.2)*
3 14.8
(4.8–45.9)**
0 0.0
(0.0–17.4)
1 0.9
(0.0–4.9)
61 Prostate 1 50.7
(1.3–282.3)*
0 0.0
(0.0–174.7)
0 0.0
(0.0–1622.2)
0 0.0
(0.0–850.4)
1 57.3
(1.5–319.1)*
0 0.0
(0.0–219.8)
62 Testis 0 0.0
(0.0–13.0)
7 1.2
(0.6–2.4)
0 0.0
(0.0–99.8)
3 2.7
(0.9–8.5)
0 0.0
(0.0–15.0)
4 0.8
(0.3–2.2)
64–66 Kidney 2 13.8
(3.5–437.5)*
3 6.8
(2.2–21.2)*
2 138.1
(34.5–552.0)***
3 44.1
(14.2–136.8)***
0 0.0
(0.0–28.4)
0 0.0
(0.0–10.0)
67–68 Bladder 1 11.7
(0.3–65.0)
3 14.0
(4.5–43.4)**
0 0.0
(0.0–397.0)
0 0.0
(0.0–123.2)
1 13.1
(0.3–72.9)
3 16.3
(5.2–50.4)**
70–72 CNS 156 45.8
(39.2–53.6)***
29 6.5
(4.5–9.4)***
153 373.4
(318.6–437.5)***
23 34.7
(23.1–52.2)***
3 1.0
(0.3–3.1)
6 1.6
(0.7–3.5)
73 Thyroid 1 54.6
(1.4–304.2)*
12 6.0
(3.4–10.5)***
1 496.6
(12.6–2767.0)**
10 32.2
(17.3–59.8)***
0 0.0
(0.0–226.3)
2 1.2
(0.3–4.7)
81 HL 0 0.0
(0.0–6.4)
8 1.8
(0.9–3.6)
0 0.0
(0.0–50.7)
1 1.3
(0.0–7.2)
0 0.0
(0.0–7.4)
7 1.9
(0.9–4.0)
82–85, 96 Non-HL 4 3.4
(1.3–9.0)*
3 1.3
(0.4–4.2)
4 26.8
(10.1–71.4)***
1 2.6
(0.1–14.4)
0 0.0
(0.0–3.6)
2 1.1
(0.3–4.3)
91–95 Leukemia 27 6.4
(4.4–9.4)***
7 2.2
(1.0–4.6)
23 45.5
(30.2–68.5)***
4 7.7
(2.9–20.4)**
4 1.1
(0.4–2.9)
3 1.1
(0.4–3.5)
00–43, 45,
47–85,
89–97
All sites except
nonmelanoma
skin cancer
251 13.7
(12.1–15.5)***
138 2.2
(1.9–2.6)***
230 101.9
(89.6–116.0)***
72 7.6
(6.1–9.6)***
21 1.3
(0.9–2.0)
66 1.2
(1.0–1.6)
Abbreviations: ICD = International Classification of Diseases; SMR, standardized mortality ratio.
aThe sites selected are those for which any cancer deaths or incident cases occurred.
bUsing Swiss rates as expecteds for Germany and Belgian rates as expecteds for both France and the Netherlands for cancer sites for which sufficient detail
was not available from home-country national rates.
cExcluding France, Germany, and Italy.
*P , 0.05; **P , 0.01; ***P , 0.001.
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Mean daily doses ofGHwere 26.0mg/kg/d for the patients
with isolated GH deficiency, 33.8mg/kg/d for those with
idiopathic short stature, and 49.5mg/kg/d for those born
small for gestational age.
The rising risk of cancer mortality in cancer patients
in relation to daily GH dose was similar for each of the
three cancer sites with sufficient deaths for such sub-
analysis (Supplemental Table 2), and also separately in
patients who were and were not known to have been
treated with any radiotherapy, with craniospinal ra-
diotherapy, and with chemotherapy (each based on
limited data on these treatments), and in subgroups by
time since starting GH treatment. Strong significant
dose-response trends were seen in every subgroup,
except where there were small numbers (not in Tables 1
through 5).
Examining site-specific cancer risks by duration since
first GH treatment (Table 5), CNS tumor mortality de-
creased significantly (P , 0.001) and HL incidence in-
creased significantly (P = 0.001), with longer follow-up.
The decreasing CNS tumor trend derived from patients
whose underlying diagnosis was cancer (P trend, 0.001)
and the HL trend from patients whose initial diagnosis
was not cancer (a wide range of noncancer diagnoses;
P trend = 0.002).
There was no indication that risk related to cumulative
GH dose (Supplemental Table 3), except that CNS tumor
mortality diminished with increasing dose in the co-
hort overall and bone cancer mortality diminished
with increasing dose in patients with an initial diagnosis
of cancer.
Discussion
GH therapy is widely used, and a range of biological data
suggest that hormone levels in the GH–IGF-1 axis may
affect cancer risks (1, 2). It is therefore important clini-
cally to determine whether cancer risks are raised by GH
treatment. Information on this has been very limited,
however. Generally, the larger studies have had short
follow-up (10–13, 16) and the studies with long follow-
up have been small. With the exception of two cohorts of
patients treated with p-hGH (6, 18, 19), the only studies
with mean follow-up of .6 years have been a cohort
examining solely leukemia as an outcome (5) and cohorts
of a few hundred GH-treated cancer patients (7, 20).
This paucity of large-scale, long-term follow-up is
important because with few exceptions [e.g., certain
cancers after immunosuppression, several causes of leu-
kemia (21)], most known causes of cancer act after a lag
period of many years, and hence, short-term follow-up
would give little information regarding risks after likely
lag periods. Furthermore, most cancer types occur almost
entirely in adulthood, so information on short-term
cancer risks after childhood treatment (i.e., when the
patient is still young) would be virtually uninformative
about risks of these malignancies. There have been almost
no published data by duration of follow-up (12), however,
and none beyond 10 years. In our cohort, for patients with
an initial diagnosis of cancer, there was no indication of
rising risk of cancer incidence or mortality with longer
follow-up. For patients with initial noncancer diagnoses,
however, cancer incidence was significantly raised beyond
Table 3. Cancer Mortality and Incidence Risks, SAGhE Cohort, for Patients in Whom a Noncancer Diagnosis
Led to GH Treatment
Outcome
(Cancer Site)
Initial Diagnosis IGF Initial Diagnosis Noncancer, Non-IGF
Cancer Mortality Cancer Incidence Cancer Mortality Cancer Incidence
n SMR (95% CI) n SIR (95% CI) n SMR (95% CI) n SIR (95% CI)
Colon and rectum 0 0.0 (0.0–12.1) 0 0.0 (0.0–5.2) 1 5.7 (0.1–31.8) 2 2.7 (0.7–10.9)
Bone 3 3.1 (1.0–9.6) 1 1.4 (0.0–8.0) 1 1.8 (0.1–10.1) 3 4.1 (1.3–12.6)*
Melanoma 1 2.6 (0.1–14.5) 3 1.5 (0.5–4.5) 0 0.0 (0.0–16.7) 4 1.5 (0.6–4.0)
Soft tissue 0 0.0 (0.0–8.2) 0 0.0 (0.0–6.0) 0 0.0 (0.0–12.7) 2 3.1 (0.8–12.6)
Cervix 0 0.0 (0.0–64.4) 7 1.1 (0.5–2.4) 0 0.0 (0.0–33.4) 8 0.8 (0.4–1.6)
Testis 0 0.0 (0.0–19.7) 3 1.0 (0.3–3.0) 0 0.0 (0.0–62.3) 1 0.5 (0.0–3.0)
Bladder 0 0.0 (0.0–83.4) 1 8.9 (0.2–49.4) 1 31.0 (0.8–172.9) 2 27.8 (7.0–111.3)**
CNS 0 0.0 (0.0–2.0) 3 1.6 (0.5–4.8) 3 2.6 (0.8–8.0) 3 1.6 (0.5–5.1)
Thyroid 0 0.0 (0.0–371.7) 0 0.0 (0.0–5.5) 0 0.0 (0.0–578.6) 2 2.0 (0.5–7.8)
HL 0 0.0 (0.0–11.5) 3 1.7 (0.6–5.4) 0 0.0 (0.0–20.3) 4 2.0 (0.8–5.4)
Non-HL 0 0.0 (0.0–5.5) 0 0.0 (0.0–3.9) 0 0.0 (0.0–10.5) 2 2.2 (0.6–8.8)
Leukemia 2 0.8 (0.2–3.4) 1 0.8 (0.0–4.2) 2 1.5 (0.4–6.1) 2 1.5 (0.4–5.9)
All sites except
nonmelanoma
skin cancer
8 0.8 (0.4–1.6) 23 1.0 (0.6–1.4) 13 2.2 (1.3–3.7)* 42 1.4 (1.1–1.9)*
Abbreviation: SMR, standardized mortality ratio.
*P , 0.05; **P , 0.01.
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Table 4. CanceraMortality and Incidence Risks, SAGhE Cohort, by Demographic and GH Treatment Variables,
and Initial Diagnosis Leading to GH Treatment
Demographic or
Treatment Variable
All Initial Diagnoses, Total Initial Diagnosis Cancer Initial Diagnosis Noncancer
Cancer Mortality Cancer Incidencec Cancer Mortality Cancer Incidencec Cancer Mortality Cancer Incidencec
n SMRb (95% CI) n SMR (95% CI) n SMRb (95% CI) n SMR (95% CI) n SMRb (95% CI) n SMR (95% CI)
Sex
Male 138 12.4
(10.5–14.6)***
52 2.2
(1.7–2.9)***
131 90.2
(76.0–107.0)***
30 7.2
(5.0–10.3)***
7 0.7
(0.3–1.5)
22 1.1
(0.7–1.7)
Female 113 15.8
(13.1–19.0)***
86 2.2
(1.8–2.7)***
99 123.1
(101.1–149.9)***
42 8.0
(5.9–10.8)***
14 2.2
(1.3–3.7)*
44 1.3
(1.0–1.7)
Country
Belgium 23 22.1
(14.7–33.3)***)
7 1.9
(0.9–4.0)
20 113.9
(73.5–176.6)***
3 5.0
(1.6–15.4)*
3 3.5
(1.1–10.8)*
4 1.3
(0.5–3.5)
France 88 9.9
(8.1–12.2)***
— 79 96.6
(77.5–120.5)***
— 9 1.1
(0.6–2.2)
—
Germany 10 11.5
(6.2–21.4)***
— 9 114.9
(59.8–220.9)***
— 1 1.3
(0.0–7.0)
—
Italy 1 1.7
(0.0–9.4)
— 0 0.0
(0.0–252.6)
— 1 1.7
(0.0–9.6)
—
The Netherlands 27 23.6
(16.2–34.5)***
22 2.5
(1.6–3.8)***
26 138.2
(94.1–203.0)***
14 9.9
(5.8–16.7)***
1 1.0
(0.0–5.8)
8 1.1
(0.5–2.2)
Sweden 30 12.9
(9.0–18.5)***
50 1.5
(1.2–2.0)**
27 120.6
(82.7–175.9)***
21 5.6
(3.6–8.6)***
3 1.4
(0.5–4.4)
29 1.0
(0.7–1.4)
Switzerland 6 19.7
(8.8–43.7)***
2 2.5
(0.6–10.1)
5 168.4
(70.1–404.5)***
2 31.0
(7.7–123.9)**
1 3.6
(0.1–20.2)
0 0.0
(0.0–5.1)
United Kingdom 66 20.7
(16.3–26.4)***
57 3.4
(2.6–4.4)***
64 87.8
(68.7–112.1)***
32 8.9
(6.3–12.6)***
2 0.8
(0.2–3.3)
25 1.9
(1.3–2.8)**
Age started
treatment (y)
0–4 9 7.1
(3.7–13.6)***
7 1.7
(0.8–3.5)
8 127.4
(63.7–254.7)***
4 16.1
(6.1–43.0)***
1 0.8
(0.0–4.6)
3 0.8
(0.2–2.4)
5–9 70 13.9
(11.0–17.6)***
46 2.5
(1.8–3.3)***
65 100.1
(78.5–127.7)***
18 7.1
(4.5–11.3)***
5 1.1
(0.5–2.7)
28 1.7
(1.2–2.5)**
10–14 149 15.4
(13.1–18.0)***
71 2.1
(1.7–2.6)***
137 108.7
(91.9–128.5)***
42 7.3
(5.4–9.9)***
12 1.4
(0.8–2.5)
29 1.0
(0.7–1.5)
15–19 23 10.0
(6.6–15.0)***
14 2.3
(1.4–3.9)**
20 70.3
(45.4–109.0)***
8 8.6
(4.3–17.2)***
3 1.5
(0.5–4.6)
6 1.2
(0.5–2.6)
P trend 0.55 1.00 0.30 0.71 0.53 0.44
Time since started
treatment (y)
0–4 103 24.4
(20.1–29.6)***
25 3.5
(2.4–5.2)***
100 184.8
(151.9–224.8)***
20 16.0
(10.3–24.9)***
3 0.8
(0.3–2.5)
5 0.9
(0.4–2.1)
5–9 78 17.2
(13.8–21.5)***
21 1.8
(1.2–2.8)*
71 124.4
(98.6–157.0)***
12 5.9
(3.4–10.5)***
7 1.8
(0.8–3.7)
9 0.9
(0.5–1.8)
10–14 37 8.2
(6.0–11.4)***
47 2.3
(1.8–3.1)***
33 60.7
(43.2–85.4)***
24 8.2
(5.5–12.2)***
4 1.0
(0.4–2.7)
23 1.3
(0.9–2.0)
15–19 25 6.7
(4.5–9.8)***
30 1.6
(1.1–2.3)*
19 45.9
(29.3–71.9)***
11 4.5
(2.5–8.2)***
6 1.8
(0.8–4.0)
19 1.2
(0.7–1.8)
$20 8 6.1
(3.1–12.3)***
15 2.7
(1.7–4.6)**
7 37.4
(17.8–78.4)***
5 6.1
(2.5–14.7)**
1 0.9
(0.0–5.0)
10 2.2
(1.2–4.0)*
P trend ,0.001 0.13 ,0.001 0.005 0.65 0.11
Duration of
treatment (y)d
,3 118 21.1
(17.6–25.3)***
40 2.8
(2.1–3.9)***
110 174.9
(145.1–210.8)***
25 10.4
(7.1–15.5)***
8 1.6
(0.8–3.2)
15 1.3
(0.8–2.1)
3–6 80 12.4
(10.0–15.5)***
52 2.7
(2.1–3.5)***
74 87.0
(69.3–109.3)***
29 8.6
(6.0–12.4)***
6 1.1
(0.5–2.4)
23 1.4
(1.0–2.2)*
$7 35 7.5
(5.4–10.4)***
33 1.9
(1.3–2.6)**
31 50.2
(35.3–71.4)***
12 4.0
(2.2–7.0)***
4 1.0
(0.4–2.6)
21 1.4
(0.9–2.2)
P trend ,0.001 0.07 ,0.001 0.006 0.76 0.77
Mean GH dose
(mg/kg/d)d
,20 37 9.6
(7.0–13.3)***
18 4.0
(2.6–6.4)***
35 64.1
(46.0–89.3)***
12 6.5
(3.7–11.4)***
2 0.6
(0.2–2.4)
6 2.3
(1.0–5.2)
20–29 94 19.5
(15.9–23.8)***
40 3.3
(2.4–4.4)***
89 102.1
(82.9–125.6)***
26 7.6
(5.2–11.2)***
5 1.3
(0.5–3.0)
14 1.6
(0.9–2.7)
30–39 52 16.8
(12.8–22.0)***
41 2.1
(1.6–2.9)***
50 178.9
(135.6–236.1)***
19 10.2
(6.5–16.0)***
2 0.7
(0.2–2.8)
22 1.3
(0.8–1.9)
$40 7 3.8
(1.8–8.0)**
11 1.1
(0.6–2.0)
5 101.5
(42.3–243.9)***
3 5.0
(1.6–15.5)*
2 1.1
(0.3–4.5)
8 0.9
(0.4–1.7)
P trend 0.39 ,0.001 ,0.001 0.59 0.74 0.05
Cumulative GH
dose (mg/kg)d
,25 91 14.9
(12.1–18.3)***
38 3.4
(2.5–4.7)***
87 108.8
(88.2–134.2)***
25 9.9
(6.7–14.6)***
4 0.8
(0.3–2.0)
13 1.5
(0.9–2.6)
25–49 73 16.9
(13.4–21.2)***
30 2.1
(1.5–3.0)***
70 108.1
(85.5–136.7)***
18 6.6
(4.1–10.4)***
3 0.8
(0.3–2.5)
12 1.0
(0.6–1.8)
50–99 36 11.1
(8.0–15.3)***
40 2.3
(1.7–3.2)***
30 79.5
(55.6–113.6)***
18 6.8
(4.3–10.9)***
6 2.1
(0.9–4.6)
22 1.5
(1.0–2.3)
(Continued)
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20 years of follow-up and there was a highly significant
increase in incidence with longer follow-up for HL
incidence. For patients with isolated growth failure,
separately, there were inconsistent findings based on
modest numbers: significant trends of incidence with
duration of treatment and time since first treatment, but
not for mean dose (P = 0.52), not clearly for cumulative
dose (P = 0.08), and not for cancer mortality. For
Turner syndrome separately, there were no consistent
or significant relations.
Potentially, the cancer risks in GH-treated patients could
reflect the underlying condition leading to GH treatment,
and the non-GH treatments (e.g., radiotherapy) given for
this condition, as well as the effect of GH itself. This is
clearest for patients receiving GH because of malignancy or
chromosomal instability syndromes, but applies to some
extent to virtually every underlying diagnosis, for example,
hypopituitarism (9, 22) or Turner syndrome (23). The
underlying diagnoses are numerous andheterogeneous, and
we do not hold systematic information on the non-GH
treatments, so we cannot give explanation of the results in
relation to specific confounders. In principle, this might be
overcome by comparing GH-treated patients with
others with the same condition who had not received
GH. This has been done in some studies for patients
with underlying cancer (7, 24, 25). We did not have
comparison data for untreated patients, however.
Furthermore, this would not entirely solve the problem
because selective factors leading to GH treatment may
themselves cause differences in cancer risk between
treated and untreated groups. Our analyses using
general population rates to generate expectations need
to be interpreted cautiously in this light.
High completeness of follow-up to a fixed end-date is
critical if cohort study results are to be valid, especially for
safety assessment, because deficient follow-up can arti-
factually produce an apparent lack of raised risk. Pre-
vious large r-hGH cohorts, with one exception (16), have
censored follow-up at last clinic visit, not at a fixed end-
date (10, 12, 13, 26). Because frequency of medical
contact depends on health status, this could be seriously
biased. The large postmarketing surveillance studies
(10–12, 14, 16) have also depended on active reporting of
cancers to the pharmaceutical company by physicians,
the completeness of which is unknown, especially after
patients leave pediatric endocrine care. Our follow-up for
mortality and cancer incidence, like that in the p-hGH
cohorts (18, 19), was to a fixed end-date, and had high
completeness through routine national data systems (15).
If GH affects cancer risk, one might expect dose- and
duration-response relationships for risk. No data have
been published on this, however: only statements of no
relation for leukemia in one cohort (5) and for overall
cancer risk in another (19). Our results did not suggest an
increase in cancer mortality or incidence risks with in-
creasing cumulative GH dose: Apparent decreases in risk
with higher doses appeared to be largely or entirely an
artifact of confounding by initial diagnosis, and apparent
increases with shorter duration an artifact of stopping
GH treatment because of cancer occurrence (see Results).
However, there was a significant increase in cancer
mortality with increasing mean daily r-hGH dose for
patients with previous cancer. Interpretation is uncertain.
Favoring a causal explanation, the association was highly
significant, so very unlikely to be due to chance; the re-
sults did not appear to be due to potentially confounding
treatments such as craniospinal radiotherapy, as far as
data were available to assess this, and the lack of similar
associations for cancer incidence or for patients with initial
noncancer diagnoses could be plausible if GH affects cancer
Table 4. Continued
Demographic or
Treatment Variable
All Initial Diagnoses, Total Initial Diagnosis Cancer Initial Diagnosis Noncancer
Cancer Mortality Cancer Incidencec Cancer Mortality Cancer Incidencec Cancer Mortality Cancer Incidencec
n SMRb (95% CI) n SMR (95% CI) n SMRb (95% CI) n SMR (95% CI) n SMRb (95% CI) n SMR (95% CI)
$100 3 2.7
(0.9–8.3)
11 1.6
(0.9–2.9)
2 34.2
(8.6–136.9)**
5 9.6
(4.0–23.1)***
1 0.9
(0.0–5.3)
6 1.0
(0.4–2.1)
P trend 0.003 0.02 0.05 0.43 0.24 0.63
Total 251 13.7
(12.1–15.5)***
138 2.2
(1.9–2.6)***
230 101.9
(89.6–116.0)***
72 7.6
(6.1–9.6)***
21 1.3
(0.9–2.0)
66 1.2
(1.0–1.6)
Abbreviation: SMR, standardized mortality ratio.
aAll malignancies except nonmelanoma skin cancer.
bUsing Swiss rates as expecteds for Germany and Belgian rates as expecteds for both France and the Netherlands for cancer sites for which sufficient detail
was not available from home-country national rates.
cExcluding France, Germany, and Italy.
dUnknown, all initial diagnoses: duration of treatment mortality = 18, incidence = 13; mean GH dose mortality = 61, incidence = 28; cumulative GH dose
mortality = 48, incidence = 19.
*P , 0.05; **P , 0.01; ***P , 0.001.
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survival rather than cancer occurrence. Against a causal
explanation is the lack of relation of risk to increasing cu-
mulativeGHdoseor treatment duration, and the existence of
potential for confounding by underlying disease or non-GH
treatment factors not captured by the relatively crude mea-
sures of these we had available. Further data are needed to
resolve whether high GH doses affect cancer survival.
For the three cancer sites for which there is most
published support for an association with IGF-1 levels—
colorectum, breast, and prostate (2)—the evidence from
our cohort and previously (9, 10, 18, 19) is too sparse to
reach a conclusion on relations to GH treatment,
reflecting the rarity of these cancers at childhood and
young adult ages. Concerns about leukemia risk after
GH were raised by case reports (5) and a significantly
raised risk in a cohort of p-hGH patients (6). However,
others (19), and cohorts that excluded “high-risk” pa-
tients (11, 12), have found no excess, although several
leukemias occurred in the high-risk group. In our co-
hort, there was a highly significant excess of leukemia
incidence and mortality confined to patients with prior
cancer. The data overall suggest that GH treatment does
not substantially increase leukemia risk in patients
without prior high risk, but leave it unclear whether risk
is affected in high-risk individuals.
A cohort study of p-hGH patients found a significant
excess of HL mortality (19). The only other cohort
findings have been a nonsignificant excess (18), or deficit
(12), based on small numbers. In our cohort, eight HL
cases occurred, a nonsignificant excess, but there was a
Table 5. Cancer Mortality and Incidence Risks, Selected Cancer Sites, SAGhE Cohort, by Duration Since First
Treatment and Initial Diagnosis Leading to GH Treatment
Cancer Site
(Outcome),
Duration
Since First
Treatment (y)
All Initial Diagnoses, Total Initial Diagnosis Cancer Initial Diagnosis Noncancer
Cancer Mortality Cancer Incidenceb Cancer Mortality Cancer Incidenceb Cancer Mortality Cancer Incidenceb
n SMRa (95% CI) n SIR (95% CI) n SMRa (95% CI) n SIR (95% CI) n SMRa (95% CI) n SIR (95% CI)
Colorectal
cancer
0–9 1 10.2 (0.3–56.7) 2 4.2 (1.1–16.9)* 1 74.4 (1.9–414.4)* 2 24.4 (6.1–97.6)** 0 0.0 (0.0–43.5) 0 0.0 (0.0–9.4)
10–19 1 2.7 (0.1–15.1) 2 2.0 (0.5–7.9) 0 0.0 (0.0–85.4) 0 0.0 (0.0–24.7) 1 3.1 (0.1–17.1) 2 2.3 (0.6–9.3)
20–29 0 0.0 (0.0–45.2) 0 0.0 (0.0–16.4) 0 0.0 (0.0–319.9) 0 0.0 (0.0–96.7) 0 0.0 (0.0–52.6) 0 0.0 (0.0–19.7)
P trend 0.25 0.25 0.11 0.06 0.97 0.75
Bone cancer
0–9 9 8.5 (4.4–16.3)*** 5 4.6 (1.9–11.0)* 7 47.8 (22.8–100.3)*** 3 14.8 (4.8–45.9)** 2 2.2 (0.5–8.7) 2 2.3 (0.6–9.0)
10–19 3 4.6 (1.5–14.2)* 4 6.8 (2.6–18.1)** 1 13.3 (0.3–74.2) 2 24.7 (6.2–98.8)** 2 3.5 (0.9–13.8) 2 3.9 (1.0–15.8)
20–29 0 0.0 (0.0–114.7) 0 0.0 (0.0–86.2) 0 0.0 (0.0–915.9) 0 0.0 (0.0–561.5) 0 0.0 (0.0–131.2) 0 0.0 (0.0–101.8)
P trend 0.30 0.76 0.19 0.82 0.76 0.74
Melanoma
0–9 0 0.0 (0.0–25.2) 2 1.6 (0.4, 6.2) 0 0.0 (0.0–178.8) 1 4.3 (0.1–23.9) 0 0.0 (0.0–29.4) 1 0.9 (0.0–5.3)
10–19 1 2.1 (0.1–11.9) 7 1.9 (0.9, 4.0) 0 0.0 (0.0–65.6) 2 3.8 (0.9–15.1) 1 2.4 (0.1–13.6) 5 1.6 (0.7–3.9)
20–29 0 0.0 (0.0–45.4) 3 4.5 (1.4, 13.8)* 0 0.0 (0.0–299.2) 2 18.9 (4.7–75.6)* 0 0.0 (0.0–53.5) 1 1.8 (0.0–9.8)
P trend 0.86 0.25 — 0.22 0.86 0.64
CNS
0–9 120 62.9 (52.6–75.2)*** 15 6.2 (3.8–10.3)*** 118 503.2
(420.1–602.7)***
11 29.3 (16.2–52.9)*** 2 1.2 (0.3–4.8) 4 2.0 (0.7–5.2)
10–19 32 24.2
(17.1–34.3)***
13 7.2 (4.2–12.4)*** 31 207.3
(145.8–294.8)***
11 43.4 (24.0–78.3)*** 1 0.9 (0.0–4.8) 2 1.3 (0.3–5.1)
20–29 4 22.9 (8.6–61.0)*** 1 4.7 (0.1–26.2) 4 155.1 (58.2–413.3)*** 1 29.8 (0.8–165.9) 0 0.0 (0.0–24.8) 0 0.0 (0.0–20.6)
P trend ,0.001 0.90 ,0.001 0.43 0.64 0.47
Thyroid
0–9 0 0.0 (0.0–1284.3) 6 10.9
(4.9–24.2)***
0 0.0 (0.0–10035.5) 5 51.3
(21.4–123.3)***
0 0.0 (0.0–1472.7) 1 2.2 (0.1–12.3)
10–19 1 78.1 (2.0–435.4)* 5 4.1 (1.7–9.8)* 1 772.6 (19.6–4304.7)** 4 22.5 (8.4–59.9)*** 0 0.0 (0.0–320.7) 1 1.0 (0.0–5.3)
20–29 0 0.0 (0.0–1393.9) 1 4.4 (0.1–24.6) 0 0.0 (0.0–10488.7) 1 28.4 (0.7–158.1) 0 0.0 (0.0–1607.5) 0 0.0 (0.0–19.3)
P trend 0.98 0.14 0.99 0.29 — 0.41
HL
0–9 0 0.0 (0.0–17.0) 0 0.0 (0.0–1.8) 0 0.0 (0.0–123.2) 0 0.0 (0.0–9.3) 0 0.0 (0.0–19.8) 0 0.0 (0.0–2.3)
10–19 0 0.0 (0.0–11.3) 6 2.7 (1.2–6.0)* 0 0.0 (0.0–95.4) 1 2.9 (0.4–20.7) 0 0.0 (0.0–12.8) 5 2.6 (1.1–6.3)*
20–29 0 0.0 (0.0–119.2) 2 9.6 (2.4–38.2)* 0 0.0 (0.0–887.9) 0 0.0 (0.0–116.5) 0 0.0 (0.0–137.7) 2 11.3 (2.8–45.1)*
P trend — 0.001 — 0.40 — 0.002
Leukemia
0–9 20 7.7 (5.0–11.9)*** 4 2.0 (0.8–5.4) 18 55.7 (35.1–88.4)*** 3 8.8 (2.9–27.4)* 2 0.9 (0.2–3.5) 1 0.6 (0.0–3.4)
10–19 7 4.7 (2.3–9.9)** 3 2.7 (0.9–8.4) 5 29.9 (12.5–71.9)*** 1 6.2 (0.2–34.3) 2 1.5 (0.4–6.1) 2 2.1 (0.5–8.4)
20–29 0 0.0 (0.0–32.6) 0 0.0 (0.0–30.5) 0 0.0 (0.0–239.3) 0 0.0 (0.0–186.3) 0 0.0 (0.0–37.7) 0 0.0 (0.0–36.5)
P trend 0.16 0.98 0.10 0.63 0.74 0.47
Abbreviation: SMR, standardized mortality ratio.
aUsing Swiss rates as expecteds for Germany, and Belgian rates as expecteds for both France and the Netherlands, for cancer sites for which sufficient
detail was not available from home-country national rates.
bExcluding France, Germany, and Italy.
*P , 0.05; **P , 0.01; ***P , 0.001.
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highly significant trend with longer follow-up (although
no trend with GH dose). The previous studies finding
raised HL risk have been those with longest follow-up, so
it remains possible that GH treatment at young ages may
affect long-term HL risk.
Our cohort showed a significant raised bone cancer
incidence in GH-treated patients, both those with and
without an initial cancer diagnosis. Bone cancer has been
one of the most common second primaries in previous
childhood GH-treated cohorts (18, 24). The few risk an-
alyses have been nonsignificant, based on very small
numbers (12, 19). The three bone cancer deaths after iso-
lated growth failure in our data were included in a French
SAGhE publication (27), but the other bone cancer deaths,
and all of the incident cases of bone cancer, were not. There
was no evidence in our data that bone cancer risk was
related to GH dose, but the significant bone cancer excess
in both cancer and noncancer patients, and the anatomical
and age distributions of bone cancer and association with
height in the general population (28), argue that the relation
needs reexamination in future data.
Bladder cancer risk was greatly and significantly (P =
0.002) raised in patients without previous cancer, but
based on small numbers. There appear to be no previous
data about this and until such data are available, little
weight can be put upon it.
We found significant excesses of incidence and mor-
tality from cancers of the soft tissue, kidney, CNS, and
thyroid, and of incidence of melanoma and cancer of the
ovary and mortality from non-HL, all restricted to pa-
tients with cancer as the reason for GH treatment.
Mainly, these are cancer sites for which raised risk of
second cancer after radiotherapy and/or chemotherapy is
well known (29, 30), although this does not preclude GH
raising the risks further. Melanoma, however, is not a
tumor usually raised after radiotherapy and chemo-
therapy, although it has been in at least one instance (31).
Only for CNS tumors are there previous data on risks
as a second malignancy after GH, with no raised risk
relating to GH (25). An excess of CNS tumors has been
found in patients treated with GH who did not have
previous malignancy (12).
Our study had weaknesses, detailed further in ref. 15.
We did not have information on GH treatment beyond
pediatric ages, so we may have underestimated treatment
duration for some patients with consequent dilution of
any true effect of duration on cancer risk. Aggregation of
data from eight countries adds the complexity of hetero-
geneity in patient mix and treatments, but without such a
pooling the large numbers and hence statistical power of
this study could not have been achieved. We did not have
information on IGF-1 levels. In addition, although our
follow-up was much longer than in previous large cohort
studies of childhood-treated patients (10–14), it still in-
cluded few person-years beyond age 35, and hence had
limited power for cancers prevalent at middle ages and
older (and indeed for cancers prevalent at younger ages:
even though the cohort is large, numbers of cases are
often not large and therefore CIs tended to be wide). In-
terpretation of our data must therefore be cautious, and
future longer follow-up of the cohort will be important. In
Germany and Italy, ascertainment of GH-treated patients
may have been substantially incomplete; in Italy, there was
incompleteness in mortality follow-up; and in France and
Italy, regulations and reimbursement rules gave incentives
to prescribers to overstate isolated growth failure as an
underlying diagnosis. These weaknesses seem unlikely to
have biased the cancer analyses presented, however, as
removal of France, Germany, and Italy from the analyses
did not alter the conclusions.
Overall, our study, with much larger numbers of GH-
treated patients followed long-term than previously, does
not suggest that GH treatment affects the risk of cancer
incidence or mortality for the outcomes and durations of
follow-up forwhich our analyses have substantial data. The
lack of increased risk with greater cumulative dose or du-
ration of treatment, key variables for which data have not
been published previously, makes a causal relation less
likely. There was also no clear raised risk in patients with
isolated growth failure. These factors argue against a major
risk of cancer overall within the length of follow-up cur-
rently available. Nevertheless, continued vigilance during
follow-up is desirable, both because of the lack of data for
longer follow-up than in our study and because of the
presence of some significant raised risks in the results. The
rising cancer mortality with greater daily dose in cancer
patients, however, leaves open the possibility of an effect on
cancer survival. Also, the raised risks of bone and bladder
cancers in patients with initial noncancer diagnoses and the
rising risk of HL with longer follow-up in such patients
leave possibilities of effects on site-specific cancer causation
for which further data are needed.
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